GENES COMMONLY
TESTED IN CANCER
Cancer-relevant gene names become meaningful when you understand what each one means for treatment options. A working map of which genes are actionable transforms an NGS report from intimidating to navigable.
Key Actionable Genes by Cancer Type
| Cancer Type | Gene / Alteration | Frequency | Matched Therapy |
|---|---|---|---|
| Lung (NSCLC) | EGFR mutations | 10-15% (up to 50% in Asia) | Osimertinib (preferred first-line) |
| Lung (NSCLC) | ALK fusions | 3-5% | Alectinib, lorlatinib, brigatinib |
| Lung (NSCLC) | KRAS G12C | ~13% | Sotorasib, adagrasib |
| Lung (NSCLC) | MET exon 14 skipping | 3-4% | Capmatinib, tepotinib |
| Breast | HER2 amplification/overexpression | 15-20% | Trastuzumab, T-DXd, tucatinib, pertuzumab |
| Breast | PIK3CA mutation | ~40% of HR+ | Alpelisib plus fulvestrant |
| Breast / Ovarian | BRCA1/2 mutations | 5-10% breast; 15-20% HGSC ovarian | Olaparib, talazoparib, niraparib (PARP inhibitors) |
| Colorectal | RAS (KRAS/NRAS) mutations | ~50% | Predicts NON-response to cetuximab/panitumumab |
| Colorectal | BRAF V600E | 8-10% | Encorafenib plus cetuximab |
| All cancers | MSI-H / dMMR | Varies by type | Pembrolizumab (tumour-agnostic approval) |
| All cancers | NTRK fusions | Rare but pan-cancer | Larotrectinib, entrectinib (tumour-agnostic) |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About the Gene Findings in Your NGS Report?
CancerFax helps patients understand which NGS findings are actionable and connects them with oncologists experienced in molecular-guided cancer treatment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.